Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NATCH: Neoadjuvant vs Adjuvant Chemo in NSCLC
NCT00913705Phase 3Completed
- Sponsor
- Fundación GECP
- Start
- Sep 1999
- Primary completion
- Dec 2007
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
01
Overview
Phase 3, randomised, open-label trial of Paclitaxel Micelles for Injection and carboplatin in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Fundación GECP. Primary endpoints: Disease-Free Survival at 5 years and Overall Survival at 5 years. Started Sep 1999; status: completed.
02
Drugs
Paclitaxel Micelles for Injectioncarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00913705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00913705.